Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Abdul Amir

Sleep Medicine Richmond, VA Medical Doctor

NPI 1255315081 CMS profile 1167527

6600 W Broad St Ste 300, Richmond, VA 23230

Open in the dashboard

General payments

$3,483

70 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Abdul Amir of Richmond, VA is reported in the CMS Open Payments database as having received $3,483 across 70 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Sleep Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $925 38
2022 General $221 4
2021 General $545 19
2020 General $1,757 7
2019 General $35 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Abdul Amir
  • Sleep Medicine median
  • Middle half of Sleep Medicine
  • National median

In program year 2025, general payments to Abdul Amir were reported at $925. Among 670 Sleep Medicine profiles paid that year, the median was $439 and the middle half received between $127 and $1,274.

Show as a table
Year Abdul Amir Sleep Medicine median Middle half National median
2019 $35 $185 $66–$736 $163
2020 $1,757 $149 $46–$504 $114
2021 $545 $191 $62–$750 $132
2022 $221 $246 $92–$972 $149
2023 $0 $321 $119–$1,033 $160
2024 $0 $393 $111–$1,207 $164
2025 $925 $439 $127–$1,274 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Inspire Medical Systems, Inc. $1,622 3 payments
  2. Tactile Systems Technology Inc $388 16 payments
  3. AstraZeneca Pharmaceuticals LP $273 9 payments
  4. Jazz Pharmaceuticals Inc. $223 6 payments
  5. Boston Scientific Corporation $99 1 payment
  6. Medtronic, Inc. $81 2 payments
  7. Cardiva Medical, Inc. $80 1 payment
  8. United Therapeutics Corporation $74 3 payments
  9. Genzyme Corporation $71 3 payments
  10. Regeneron Healthcare Solutions, Inc. $61 3 payments
  11. Other $511 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,956 68 payments
  2. Travel and Lodging $1,428 1 payment
  3. Education $100 1 payment
Products named General payments · program years 2019–2025
  1. Inspire Upper Airway Stimulation System $1,601 2 payments
  2. Flexitouch Plus $344 13 payments
  3. entre $344 13 payments
  4. XYWAV $223 6 payments
  5. FARXIGA $125 1 payment
  6. VARITHENA $99 1 payment
  7. TEZSPIRE $85 4 payments
  8. Vascular Closure Device $80 1 payment
  9. TYVASO $74 3 payments
  10. DUPIXENT $71 3 payments
  11. Other $969 45 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 41 drugs

Part D claims

1,050

Median for Internal Medicine: 777

Drug cost

$22,505

Median for Internal Medicine: $73,373

Branded share of claims

11%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 16 $7,593
Eliquis Apixaban Brand 13 $4,066
Hydroxychloroquine Sulfate Generic 12 $1,098
Memantine Hcl Generic 13 $884
Quetiapine Fumarate Generic 103 $748
Cefdinir Generic 52 $682
Levothyroxine Sodium Generic 61 $653
Captopril Generic 12 $597
Carvedilol Generic 43 $556
Metoprolol Succinate Generic 50 $545

The 10 drugs with the highest cost, of 41 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$47,065

Medicare's payments for the services billed

Medicare patients

244

Average age 73

Services billed

573

109 women, 135 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Diabetes 46%
Chronic kidney disease 44%
Depression 44%
Ischemic heart disease 41%
Heart failure 36%
Atrial fibrillation 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

70 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sleep Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record